Prilosec Lawsuit

If you or a loved one have developed chronic kidney disease or suffered kidney failure after daily use of prescription or over-the-counter strengths of brand-name Prilosec, you may be eligible for compensation. 

Prilosec and Chronic Kidney Disease

prilosec lawsuitA recent study has shown that Prilosec and other Proton Pump Inhibitor (PPI) medications may increase the risk of developing chronic kidney disease. You may be eligible for financial compensation through a Prilosec lawsuit if you or a loved one have experienced chronic kidney disease or other serious medical injury after taking Prilosec.

In February of 2016, JAMA, the Journal of the American Medical Association published results of a study showing that people who take Prilosec and other Proton Pump Inhibitor (PPI) medications may have a 20 to 50 percent increased risk of chronic kidney disease (CKD). The longer the medication is taken, the greater the risk.

This is not the first safety concern that has been raised by Prilosec, with issues reaching back to 2002. Prilosec has been shown to:

  • Increase the risk of chronic kidney disease
  • Increase the risk of heart attack
  • Increase the risk of bone fracture
  • Increase the risk of low magnesium levels or hypomagnesemia

Patients or their families may be eligible for compensation for medical costs, loss of wages and pain and suffering due to medical injury caused by Prilosec. If the medication’s use resulted in a death, family members may be eligible for wrongful death damages awarded in a Prilosec lawsuit.

Past lawsuits filed against drug manufacturers whose medications resulted in injury have claimed that those companies:

  • Produced a dangerous or defective drug
  • Failed to provide adequate warnings about risks of drug
  • Knowingly hid dangers of medication from public and medical community
  • Marketed the medication in an improper or illegal way

Some victims have filed Prilosec lawsuits in the past for other injuries but no settlements have been reached. This new information regarding increased risk of chronic kidney disease may mean that more patients will do so.

Filing a lawsuit against a drug manufacturer carries no guarantee of success or settlement and each potential case of medical injury must be evaluated separately.

About Prilosec

Prilosec (omeprazole) is a proton-pump inhibitor (PPI) which works to treat gastroesophageal reflux disease (GERD) by preventing the release of acid in the stomach. Prilosec has been used by millions of people, but it has been shown increase the risk of heart attack, bone fracture and other serious conditions. Multiple Prilosec lawsuits have already been filed against manufacturer, Astra Zeneca for injuries caused by its use.

Prilosec was the first PPI medication, approved in the U.S. in 1989. The PPI class of medications now includes Nexium, Prevacid and several others which have been some of the best-selling drugs in history, making billions of dollars for Astra Zeneca and the other manufacturers. Up to 14% of U.S. adults have taken a prescription PPI medication and many more have used the OTC versions.

Prilosec, Nexium and Prevacid were also approved as over-the-counter (OTC) medications because they were believed to be safe enough for use without a doctor’s prescription but the drugs have not been without controversy. Concern has been raised about an increased risk of hip fracture, cardiac birth defects, and heart attack risk when taking Prilosec and other PPIs.

Prilosec Serious Side Effects

Prilosec has been the subject of multiple warnings, the most recent of which came in 2015 but trouble started shortly after its approval. It had initially been released under the name “Losec”, unfortunately similar to a common antidiuretic. The similarity resulted in a number of medication errors and at least one death the name had to be changed to “Prilosec”. Other issues of Prilosec have included:

  • Bone fractures – In 2006, a medical journal reported that Prilosec could increase the risk of bone fracture, particularly in the elderly. An FDA consumer warning was finally issued and a labeling change was required in 2010 regarding the increased bone fracture risk.
  • Acid rebound – In 2009, Prilosec was shown to cause “dependency”. Researchers showed that if the medication was discontinued, the stomach may suddenly begin releasing too much acid.
  • Birth defects – In 2010, concern was raised about a link between cardiac birth defects and Prilosec use. The FDA stated that there wasn’t a statistical link for humans but studies in animals have confirmed the risk. Prilosec is currently listed as Pregnancy Category C and should not be taken by pregnant women unless urgently needed.
  • Hypomagnesemia – In 2011, another warning was issued regarding low magnesium levels that may be caused by Prilosec. Hypomagnesemia may affect the way nerves and muscles work and may also have effects on the heart.
  • Intestinal infection – In 2012, the FDA issued a warning regarding the increased risk of a serious gastrointestinal illness, Clostridium difficile (C diff), particularly in the elderly. Labeling was changed to include the C difficile warning, along with information about drug interactions and how long Prilosec should be used.
  • Heart attack – In 2015, results of two large studies indicated an increase in heart attack risk. The studies examined nearly 3 million people who had taken Prilosec or other PPIs and found that heart attack risk may increase by 16 to 21%, even in patients who did not have a history of cardiac disease.
  • Vascular aging – In 2016, researchers concluded that PPI use may prematurely “age” cells of the vascular system. This may contribute to age-related illness such as dementia, renal failure, cardiovascular disease and cancer, though no definitive connection has been made.
  • Kidney damage – In 2016, study results published in a respected medical journal indicated that long-term use could contribute to development of chronic kidney failure or renal disease.

Some medical professionals have said that up to 70% of PPI use may not be indicated and the drugs may be used for much longer than appropriate. Prilosec has been the subject of multiple lawsuits for birth defects, fractures and serious effects caused by low magnesium or other factors related to PPI use.

Prilosec Common Side Effects

Most of the side effects of Prilosec are mild to moderate and may go away over time. If symptoms persist or become bothersome, they should be reported to a medical professional. Common side effects of Prilosec include:

  • Joint or muscle pain
  • Nausea, diarrhea, intestinal pain
  • Unpleasant aftertaste
  • Headache
  • Dizziness
  • Anxiety
  • Rash

In some cases, side effects may be more serious and may become life-threatening.   Severe or serious side effects include:

  • Bullseye rash (Erythema Multiforme) or other severe rashes
  • Heart rhythm changes, heart attack
  • Low magnesium symptoms – speech disorder, confusion, loss of consciousness, seizure
  • Bone fracture
  • Birth Defects

Serious side effects should be reported to a healthcare immediately.

More on Prilosec Lawsuits

Concerns about Prilosec and PPI safety have continued to emerge but the medications continue to be prescribed and sold over-the-counter. Astra Zeneca, Prilosec’s manufacturer is facing a number of lawsuits due to injuries and birth defects related to the medication.

Plaintiffs are suing for compensation for medical costs, lost wages, and pain and suffering and in some cases, may be seeking punitive damages. There are no guarantees and each case must be considered separately but patients or loved ones of those who suffered heart attack, birth defect, bone fracture or other serious effects of Prilosec should seek legal advice.

View Sources
  1. American Gastroenterological Association (02 July 2009), Acid-reducing Medicines May Lead To Dependency, Science Daily, Accessed on 01 October 2015 http://www.sciencedaily.com/releases/2009/07/090701082909.htm
  2. Associated Press, 26 May 2010, New warning on heartburn drugs: bone fracture risk, Consumer Reports News, Accessed on 01 October 2015 http://www.consumerreports.org/cro/news/2010/05/new-warning-on-heartburn-drugs-bone-fracture-risk/index.htm
  3. DeNoon, D., (17 November 2009), FDA Warns Plavix Patients of Drug Interactions, WebMD Health News, Accessed on 01 October 2015 http://www.webmd.com/heart-disease/news/20091117/fda-warns-plavix-patients-drug-interactions
  4. Drugs.com, (2015), Proton Pump Inhibitors, Drugs.com List, Accessed on 01 October 2015 http://www.drugs.com/drug-class/proton-pump-inhibitors.html
  5. Drugs.com, (2014), Top 100 Drugs by Sales, Drugs.com, Accessed on 01 October 2015 http://www.drugs.com/stats/top100/2013/sales
  6. Florentin, M., et al, (06 December 2010), Proton pump inhibitor-induced hypomagnesemia: A new challenge, World Journal of Nephrology, Accessed on 01 October 2015 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782221/
  7. FDA Drug Information, (2015), Prilosec, RxList.com, Accessed on 01 October 2015 http://www.rxlist.com/prilosec-drug.htm
  8. Food and Drug Administration, (25 May 2010), For Consumers: Possible Increased Risk of Bone Fractures With Certain Antacid Drugs. U.S. Food and Drug Administration, Accessed on 01 October 2015 http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm213240.htm
  9. Food and Drug Administration (02 March 2011), FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs), U.S. Food and Drug Administration, Accessed on 01 October 2015 http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm
  10. Leri, F., et al, (April 2013), Four-year trends of inappropriate proton pump inhibitor use after hospital discharge, Southern Medical Journal, Accessed on 01 October 2015 http://www.ncbi.nlm.nih.gov/pubmed/23558416
  11. Mazer-Amirshah, M., et al, (June 2014), Rising rates of proton pump inhibitor prescribing in US emergency departments, American Journal of Emergency Medicine, Accessed on 01 October 2015 http://www.ncbi.nlm.nih.gov/pubmed/24721025
  12. Moukheiber, Z., (18 March 2002), Modesty Ablaze, Forbes, Accessed on 01 October 2015 http://www.forbes.com/forbes/2002/0318/066.html
  13. Norton, A., (10 June 2015), Popular Heartburn Meds Tied to Heart Attack Risk, HealthDay, Accessed on 01 October 2015 http://www.webmd.com/heartburn-gerd/news/20150610/popular-heartburn-meds-linked-to-higher-risk-of-heart-attack
  14. NYSE, (01 October 2015), AstraZeneca Financials (AZN), Google Finance, Accessed on 01 October 2015 https://www.google.com/finance?q=NYSE%3AAZN&fstype=ii&ei=Yj4MVqn1GoSH2Aah_6noDw
  15. Ogbru, O., (12 June 2015), Proton-Pump Inhibitors (PPIs), Medicine Net, Accessed on 01 October 2015 http://www.medicinenet.com/proton-pump_inhibitors/article.htm
  16. Perks, B., (16 June 2015), Proton pump inhibitors are associated with increased risk of heart attack, The Pharmaceutical Journal, Accessed on 01 October 2015 http://www.pharmaceutical-journal.com/news-and-analysis/news/proton-pump-inhibitors-are-associated-with-increased-risk-of-heart-attack/20068748.article
  17. Reimer, C., et al, (July 2009), Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy, Gastroenterology, Accessed on 01 October 2015 http://www.gastrojournal.org/article/S0016-5085%2809%2900522-8/fulltext
  18. Richter, J., (2005), Review Article: The Management of Heartburn in Pregnancy, Alimentary Pharmacology & Therapeutics, Accessed on 01 October 2015 http://www.medscape.com/viewarticle/515100_5
  19. Shah, N., et al, (10 June 2015), Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population, PLOS-One, Accessed on 01 October 2015 http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0124653&representation=PDF
  20. Splete, H., (01 December 2010), PPIs Might Raise Risk of Cardiac Birth Defects, Skin & Allergy News, Accessed on 01 October 2015 http://www.edermatologynews.com/index.php?id=1059&type=98&tx_ttnews[tt_news]=121958&cHash=da03e20e36
  21. Statistica, (2014), Top 10 OTC brands by revenue in the U.S. in 2013, Statistica Statistics Portal, Accessed on 01 October 2015 http://www.statista.com/statistics/296116/top-10-over-the-counter-brands-by-us-revenue/
  22. First Word Pharma, (14 August 2012), ViewPoints: Pfizer eyes OTC opportunities both home and abroad, First Word Pharma, Accessed on 01 October 2015 http://www.firstwordpharma.com/node/1010875?tsid=17#axzz3nFlLf0Mj
  23. Gaunt, M., (11 March 2014), Older Drugs Are Still Involved in Mix-ups, Pharmacy Times, Accessed on 01 October 2015 http://www.pharmacytimes.com/publications/issue/2014/march2014/older-drugs-are-still-involved-in-mix-ups